Clinical Trial

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma

Study acronym: NEO-GLITIPNI
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2025 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this phase I interventional study is to determine the safety and feasibility of the proposed investigational (neo-)adjuvant treatment regimen in patients with resectable reccurent glioblastoma. Participants will: * receive neo-adjuvant administration of intravenous immunotherapy * followed by a maximal safe neurosurgical resection * afterwards, immunotherapy will be injected into the brain tissue * followed by insertion of an Ommaya reservoir * postoperatively, administration of immunotherapy will be continued
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-23.
Status change: Not Yet Recruiting → Recruiting 2025-01-16
Trial Details
NCT Number NCT06097975
Lead Sponsor Universitair Ziekenhuis Brussel
Conditions Recurrent Glioblastoma
Enrollment 18 participants
Start Date 2024-03-15
Primary Completion 2025-06-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-20